Thus, in MM patients, 1q21 amplification promotes ADAR1 overexpression, and during cancer progression, as shown in other malignancies, inflammatory cytokine signaling may promote ADAR1 expression leading to poorer clinical outcomes7,11. Here, ADAR is linked to Miyoshi myopathy.